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A 77-year-old male is presented. He had onset of proximal weakness 10 years earlier. His course was slowly progressive. Despite
having phenotypic features of facioscapulohumeral muscular dystrophy (FSH), genetic testing for this was delayed because of
his age of onset, lack of family history, and benign appearing muscle biopsy. This case is one of the oldest onset of weakness in
genetically confirmed FSH and highlights the recognized expansion in phenotype that has occurred since the advent of genetic
testing.
1. Introduction
Facioscapulohumeral Muscular Dystrophy (FSH) is the third
most common muscular dystrophy. It predominately results
in weakness of facial, shoulder, and upper arm muscles with
onset of symptoms in most individuals prior to age 20-
year-old (yo). Around 95% of individuals with FSH have a
deletion in the 3.3 kb D4Z4 repeat segment on chromosome
4; interestingly, and confusing for assessing this, the deletion
is only pathologic with hypomethylation of DNA, occurring
on specific D4Z4 alleles and having at least one repeat present
[1, 2]. With the advent of genetic testing, the accepted
phenotypic expression has expanded [2, 3]. However, there
are still patients who challenge the notion of what is an
accepted initial presentation for FSH.
This paper describes a patient who had onset of weakness
in his seventh decade of life and had no dystrophic changes
on muscle biopsy. Because of his pattern of weakness, FSH
genetic testing was performed and confirmed the diagnosis.
This is one of the oldest age of symptom onset reported in a
genetically confirmed FSH patient [4–6].
2. Case Report
The patient presented at 77-year-old with an approximately
ten-year history of slowly progressive shoulder and proximal
arm weakness and one-year history of speaking and swallow-
ing difficulties with rare dyspnea on exertion. Throughout
his life he was physically very active includingmilitary service
(National Guard) until retiring at age 60-year-old, outdoor
activities, karate, and violin. At 65-year-old, he stopped
karate because of concern of injury from sparring with much
younger individuals; at that same age he also stopped playing
violin because of poor finger control. It was not, though,
until a few years later that he developed his presenting
complaints.
His past medical history was significant for mild-type
II diabetes mellitus, recent gastrointestinal bleed, coronary
artery disease with stenting three years prior to presenta-
tion, cataracts, and bilateral knee replacements four years
prior to presentation. Medications included simvastatin,
aspirin, metoprolol, niacin, lansopraxole, metformin, meto-
clopramide, as needed nitroglycerin, and various vitamins
and minerals. His family history was significant for coronary
artery disease on the paternal side and diabetes mellitus on
the maternal. There is no family history of early onset muscle
weakness. Other aspects of his social history and review of
systems were unremarkable.
On physical exam, his vitals and general examination
were unremarkable. On neurological examination, mental
status, reflex, and sensory examinations were appropriate
for his age. On cranial nerve examination, the patient had
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Figure 1: Trichrome stained muscle biopsy, 20x magnification lens.
The sole degenerating fiber in the entire biopsy is in the bottom left
corner (arrow). There are no dystrophic changes present.
dysarthric speech, predominately slurred, and bilateral facial
weakness, 4/5 on the Medical Research Council (MRC)
scale unable to fully purse lips. There was no worsening of
weakness with sustained activity. Other aspects of the cranial
nerve examination were unremarkable. Motor examination
revealed weakness predominately proximal and in the upper
extremities. Shoulder abduction was 4−/5, rest of the upper
extremity was 4+/5, hip flexion 4−/5, and rest of lower
extremities was 5−/5 on the Medical Research Council
(MRC) scale. There was atrophy of the shoulder girdle, mild
atrophy of intrinsic muscles of his feet, and decreased tone
throughout. His gait was broad based and slow.
Testing done one year prior to presentation was signifi-
cant for myopathic, short duration with low amplitude, units
in proximal, upper extremity muscles on nerve conduction
studies/electromyography testing (NCS/EMG), borderline
creatine kinase (250U/L, normal (n) 150–230U/L), serial
swallowing studies demonstrating new onset difficulties,
and degenerative changes appropriate for age on magnetic
resonance imaging (MRI) of the cervical spine. The following
were unremarkable-acetylcholine receptor antibodies, thy-
roid function tests, complete metabolic panel, erythrocyte
sedimentation rate, serum protein electrophoresis, and MRI
of the brain. Chest X-ray was significant for flattened hemidi-
aphragms, scattered calcifications, and linear scarring; the
changes were concerning for chronic obstructive pulmonary
disease and were unchanged over four years. Cardiac
consultation including echocardiogram and catherization
was unremarkable. The referring neurologist was already
concerned for a muscular dystrophy.
At presentation, pulmonary function testing (PFTs) and
a muscle biopsy were ordered. The PFTs were unremarkable
(FVC 98% predicted, FEV1 91% predicted). The muscle
biopsy of the deltoid was similarly unremarkable; there was a
single degenerating myofiber with lymphocytic infiltration,
a couple areas of minor, perivascular inflammation, and a
few muscle fibers with increased internal nuclei, Figure 1.
His simvastatin was halted without any improvement. A
trial of prednisone was initiated and halted when it leads
to worsening symptoms. Four months after presentation,
repeat testing was performed. An NCS/EMG study including
repetitive stimulation was similar to prior studies; there
were some changes on the EMG aspect suggesting proximal
myopathy. The following blood work was unremarkable
antinuclear antibodies, erythrocyte sedimentation rate, com-
plete blood count, creatine kinase, rheumatoid factor, lac-
tate, immunofixation, parathyroid hormone panel, pyruvate,
hemoglobin A1c, thyroid stimulating hormone; a complete
metabolic panel had elevated glucose (still tapering pred-
nisone) and genetic testing for FSH which was abnormal
(one allele with 30 kb, other > 48 kb; nl > 42 kb, pathologic
12–37 kb). Based on the genetic testing a diagnosis of FSH
was made. Although his pattern of weakness at presentation
suggested FSH, his age of onset suggested another etiol-
ogy being present. The lack of dystrophy changes on the
muscle biopsy with some nonspecific inflammatory changes
prompted the steroid trial for possible polymyositis.
The patient had progressive speech, swallowing, and
breathing problems. He had an unremarkable esopha-
gogastroduodenoscopy. Pulmonary consultation including
sleep study felt that a central hyperventilation syndrome
was present, given an arterial blood gas with low PCO2
(26.6mm HG, nl 35–45), with nl PH and PO2 and stable
pulmonary function testing—FVC 97% predicted and FEV1
95% predicted. A trial of paroxetine for the hyperventilation
syndrome was unrewarding. The combination of pyridostig-
mine and oral albuterol did lessen the shortness of breath;
physical therapy improved extremity functioning.
The patient continued with a slow decline until three
years after presentation when he had a myocardial infarction
requiring stenting. His cardiac ejection fraction declined
to 25%; it was 51% three years prior; it subsequently
improved to 40%. His breathing dramatically worsened,
but his oxygen saturation on room air remained above
92%. Eight months after this event, he had another cardiac
event with a precipitous decline. He became wheelchair
bound, required percutaneous endoscopic gastrostomy tube
to prevent aspiration, and became supplemental oxygen
dependent. A little over four years after presentation, the
patient died from cardiopulmonary complications.
3. Discussion
Typically, 95% of patients with FSH have signs and symp-
toms by 20 years of age and have dystrophic changes on
muscle biopsy [3]. This patient did not. Obviously with the
advent of genetic testing, individuals have been confirmed
to have FSH who have features desperate from the typical
phenotype.
One of the current thrusts of investigating genetic
conditions is why there are significantly different pheno-
types. Two simple explanations are different environmental
exposures and different mutation in the same gene resulting
in different protein shape/function and expression. However,
it is also felt that there are additional genes that can modify
expression. Investigating these in FSH has been very difficult,
mainly, because the specific genetic abnormality has only
recently been identified [1].
The patient’s age and benign appearing biopsy suggest
that modifying genes are present which affect expression
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beyond the repeat length differences. It is unknown what
precisely causes dystrophic changes in muscular dystrophies
and what is the correlation between dystrophic changes and
phenotype; however, this patient lacked any evidence of
dystrophic changes despite being in his eighth, nearing ninth,
decade of life. His benign appearing muscle biopsy did delay
diagnosis which put him at risk from complications of a
therapeutic trial of prednisone.
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